SpectralBench
Determine your spectroscopy software's FDA regulatory pathway in 5 questions
Building spectroscopy software for clinical use? The FDA's Software as a Medical Device (SaMD) framework determines whether your software requires regulatory clearance — and which pathway applies. Getting this classification right early saves months of rework and hundreds of thousands in consulting fees.
This interactive wizard walks you through the key questions the FDA considers when classifying SaMD: what your software does with spectral data, the clinical significance of the condition, the intended user, and your spectroscopy modality. In five steps, you'll receive a preliminary classification (Class I, II, or III), the recommended regulatory pathway (510(k), De Novo, or PMA), estimated timelines and costs, and a tailored checklist of next steps.
Based on FDA guidance documents and the IMDRF SaMD risk categorization framework. This tool provides educational guidance only — not regulatory advice.
The International Medical Device Regulators Forum (IMDRF) established the global framework that the FDA uses to categorize SaMD risk. The framework evaluates two dimensions: the significance of the information provided by the software (inform, diagnose, or treat) and the state of the healthcare condition (non-serious, serious, or critical).
For spectroscopy-based SaMD, common scenarios include Raman tissue classification for cancer detection (typically Class II–III), FTIR-based pathogen identification (Class II), and NIR monitoring for process analytical technology (often Class I or non-SaMD). The modality itself doesn't determine the class — it's the clinical intent and autonomy of the software that matters.
Understanding this framework early in development lets you design your spectral analysis pipeline with the right level of validation, documentation, and quality controls from the start — rather than retrofitting them before submission.
Spectroscopy SaMD faces unique regulatory challenges. Unlike imaging-based diagnostics with extensive predicate device history, spectroscopic techniques — particularly SERS, terahertz, and multimodal approaches — may have limited or no FDA-cleared predicates. This often pushes novel spectroscopy SaMD toward the De Novo pathway, which, while more time-consuming, establishes your device as the predicate for future competitors.
Key documentation areas for spectroscopy SaMD include analytical validation of your spectral processing algorithms (preprocessing, baseline correction, peak fitting), reproducibility across instruments and operators, and clinical validation against reference methods. The FDA expects you to demonstrate that your peak identification or classification algorithms perform reliably across the range of clinical samples they will encounter.
Software as a Medical Device (SaMD) is software intended to be used for medical purposes without being part of a hardware medical device. The FDA regulates SaMD under a risk-based framework developed by the International Medical Device Regulators Forum (IMDRF). Examples include diagnostic algorithms that analyze spectroscopic data to identify diseases, or software that provides treatment recommendations based on spectral biomarkers.
The FDA classifies SaMD into three risk categories: Class I (lowest risk, general controls), Class II (moderate risk, special controls, typically 510(k) or De Novo), and Class III (highest risk, premarket approval). Classification depends on the significance of the information provided by the software, the seriousness of the healthcare condition, and the level of clinical oversight. Software that only displays data without interpretation is generally not considered SaMD.
The 510(k) pathway requires demonstrating substantial equivalence to an existing cleared device (predicate). De Novo is for novel, low-to-moderate risk devices with no suitable predicate — it creates a new classification. PMA (Premarket Approval) is the most stringent pathway for high-risk Class III devices, requiring clinical trial data. For spectroscopy SaMD, 510(k) is common when predicate devices exist for modalities like FTIR or Raman, while De Novo may be needed for novel techniques like SERS.
It depends on the intended use. Software that acquires, displays, or transfers spectral data without clinical interpretation is generally not SaMD. Software that processes spectral data to inform clinical decisions — such as identifying disease biomarkers, classifying tissue samples, or recommending treatments — likely qualifies as SaMD. The key factor is whether the software's output is intended to drive medical decisions. Use the wizard above to assess your specific situation.
Research Use Only (RUO) products are exempt from FDA premarket review but must be clearly labeled and cannot be marketed for clinical diagnostic use. RUO is appropriate for laboratory research tools that are not intended for clinical decision-making. However, the FDA may challenge an RUO designation if evidence suggests the product is actually being used or promoted for clinical purposes.
Timelines vary significantly by pathway. A 510(k) submission typically takes 6–12 months total (about 90 days of FDA review). De Novo classification takes 12–24 months (about 150 days of FDA review). PMA can take 2–5 years including clinical trials. These timelines include preparation time — the actual FDA review period is shorter, but preparing a complete submission with all required documentation and testing is the major time investment.